Skip to content

Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery

Preoperative Pain-Risk Screening and Intervention for Intraoperative Pain in Second-Eye Cataract Surgery Based on Iris Vascular Area Density

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07291089
Enrollment
126
Registered
2025-12-18
Start date
2024-02-23
Completion date
2025-12-31
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Cataract, Pain Management During Cataract Surgery

Keywords

Cataract surgery, Pain, Second-eye cataract surgery

Brief summary

This clinical trial aims to evaluate the effectiveness of pranoprofen or prednisolone acetate eye drops for pain management in patients undergoing second-eye surgery for age-related cataracts. Researchers will compare pranoprofen or prednisolone acetate eye drops with sodium hyaluronate eye drops to determine whether pranoprofen or prednisolone acetate eye drops can relieve intraoperative pain during second-eye cataract surgery. Participants will: 1. Receive one drop in the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery (pranoprofen, prednisolone acetate, or sodium hyaluronate) 2. Undergo cataract surgery and routine postoperative follow-up 3. Within 1 hour after surgery, provide a pain visual analog scale (VAS) score under the guidance of the investigator

Interventions

DRUGPranoprofen eye drops

Participants receive one drop of pranoprofen instilled into the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery.

DRUGPrednisolone acetate eye drops

Participants receive one drop of prednisolone acetate instilled into the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery.

Participants receive one drop of sodium hyaluronate instilled into the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery.

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged ≥ 50 years. * Definite diagnosis of age-related cataract. * The first-eye cataract surgery under local anesthesia has been completed at this hospital, and the second-eye cataract surgery under local anesthesia is planned with the same surgeon within 1 year of the first-eye surgery. * Able to cooperate with preoperative iris optical coherence tomography angiography (OCTA) examination of the operative eye. * On the day of the second-eye surgery, preoperative iris vascular area density (VAD) ≥ 0.2167 in the operative eye.

Exclusion criteria

* History of ocular trauma, ocular surgery (excluding the first-eye cataract surgery already performed), uveitis, chorioretinal disease, glaucoma; * Presence of significant corneal disease, marked iris abnormalities, or any active ocular surface disease, including recent conjunctivitis, keratitis, or severe dry eye. * Severe complications during or after the first-eye surgery (e.g., posterior capsule rupture, zonular dialysis, dislocation of the lens nucleus into the vitreous cavity, postoperative endophthalmitis, or glaucoma). * History of chronic pain syndromes or neuropathic pain. * Long-term use of opioids, other systemic analgesics, or sedative-hypnotic drugs. * Known autoimmune disease or ongoing immunosuppressive therapy. * Severe psychiatric disorders or cognitive impairment interfering with pain assessment. * Use of topical corticosteroid eye drops in the second eye within 1 month prior to the planned surgery. * Long-term use of α-adrenergic blockers or other medications associated with intraoperative floppy iris syndrome (IFIS). * Participation in any other clinical trial involving ophthalmic or systemic drugs within the past 6 months. * Known allergy or contraindication to topical nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., pranoprofen) or topical corticosteroids (e.g., prednisolone acetate) used in this study.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Participants With Intraoperative Pain VAS ≥ 3 (Significant Pain)Within 1 hour after surgeryIntraoperative pain is assessed within 1 hour after surgery using a 0-10 visual analog scale (VAS; 0 = no pain, 10 = most severe pain). The investigator presents the unmarked side to the participant to mark perceived intraoperative pain; the investigator reads the corresponding value on the marked reverse side and records the score. The primary endpoint is the proportion of participants with VAS ≥ 3.

Secondary

MeasureTime frameDescription
Intraoperative Pain VAS ScoreWithin 1 hour after surgeryVAS score on a 0-10 scale, obtained with the same standardized method as the primary outcome.
Patient-Reported Comparison of Second-Eye vs First-Eye Intraoperative PainWithin 1 hour after surgeryWithin 1 hour after surgery, participants are asked to select one statement that best describes how pain during the second-eye surgery compares with their first-eye experience: 1. "More painful than the first eye"; 2. "Less painful than the first eye"; 3. "About the same as the first eye"; 4. "I do not remember the pain during the first eye." The selected response is recorded.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026